Explore the critical gaps in generic availability for combination NTI drugs. Learn about bioequivalence challenges, safety risks, and FDA regulations affecting patient care.
Tag: FDA guidelines
Bioequivalence testing for combination products like fixed-dose combos and drug-device systems is far more complex than for single drugs. Regulatory hurdles, inconsistent methods, and high costs delay generic access - but new modeling tools are starting to change that.